Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation

Standard

Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation. / Merkens, Lina; Sailer, Verena; Lessel, Davor; Janzen, Ella; Greimeier, Sarah; Kirfel, Jutta; Perner, Sven; Pantel, Klaus; Werner, Stefan; von Amsberg, Gunhild.

in: J EXP CLIN CANC RES, Jahrgang 41, Nr. 1, 46, 02.02.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ReviewForschung

Harvard

APA

Vancouver

Bibtex

@article{8d3949b9ecdf4b9c8f3eb84f100e5e1b,
title = "Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation",
abstract = "Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activation is broadly used and continually improved. However, a subset of patients eventually progresses to castration-resistant disease. To date, various mechanisms of resistance have been identified including the development of AR-independent aggressive variant prostate cancer based on neuroendocrine transdifferentiation (NED). Here, we review the highly complex processes contributing to NED. Genetic, epigenetic, transcriptional aberrations and posttranscriptional modifications are highlighted and the potential interplay of the different factors is discussed. Background Aggressive variant prostate cancer (AVPC) with traits of neuroendocrine differentiation emerges in a rising number of patients in recent years. Among others, advanced therapies targeting the androgen receptor axis have been considered causative for this development. Cell growth of AVPC often occurs completely independent of the androgen receptor signal transduction pathway and cells have mostly lost the typical cellular features of prostate adenocarcinoma. This complicates both diagnosis and treatment of this very aggressive disease. We believe that a deeper understanding of the complex molecular pathological mechanisms contributing to transdifferentiation will help to improve diagnostic procedures and develop effective treatment strategies. Indeed, in recent years, many scientists have made important contributions to unravel possible causes and mechanisms in the context of neuroendocrine transdifferentiation. However, the complexity of the diverse molecular pathways has not been captured completely, yet. This narrative review comprehensively highlights the individual steps of neuroendocrine transdifferentiation and makes an important contribution in bringing together the results found so far.",
author = "Lina Merkens and Verena Sailer and Davor Lessel and Ella Janzen and Sarah Greimeier and Jutta Kirfel and Sven Perner and Klaus Pantel and Stefan Werner and {von Amsberg}, Gunhild",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = feb,
day = "2",
doi = "10.1186/s13046-022-02255-y",
language = "English",
volume = "41",
journal = "J EXP CLIN CANC RES",
issn = "1756-9966",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation

AU - Merkens, Lina

AU - Sailer, Verena

AU - Lessel, Davor

AU - Janzen, Ella

AU - Greimeier, Sarah

AU - Kirfel, Jutta

AU - Perner, Sven

AU - Pantel, Klaus

AU - Werner, Stefan

AU - von Amsberg, Gunhild

N1 - © 2022. The Author(s).

PY - 2022/2/2

Y1 - 2022/2/2

N2 - Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activation is broadly used and continually improved. However, a subset of patients eventually progresses to castration-resistant disease. To date, various mechanisms of resistance have been identified including the development of AR-independent aggressive variant prostate cancer based on neuroendocrine transdifferentiation (NED). Here, we review the highly complex processes contributing to NED. Genetic, epigenetic, transcriptional aberrations and posttranscriptional modifications are highlighted and the potential interplay of the different factors is discussed. Background Aggressive variant prostate cancer (AVPC) with traits of neuroendocrine differentiation emerges in a rising number of patients in recent years. Among others, advanced therapies targeting the androgen receptor axis have been considered causative for this development. Cell growth of AVPC often occurs completely independent of the androgen receptor signal transduction pathway and cells have mostly lost the typical cellular features of prostate adenocarcinoma. This complicates both diagnosis and treatment of this very aggressive disease. We believe that a deeper understanding of the complex molecular pathological mechanisms contributing to transdifferentiation will help to improve diagnostic procedures and develop effective treatment strategies. Indeed, in recent years, many scientists have made important contributions to unravel possible causes and mechanisms in the context of neuroendocrine transdifferentiation. However, the complexity of the diverse molecular pathways has not been captured completely, yet. This narrative review comprehensively highlights the individual steps of neuroendocrine transdifferentiation and makes an important contribution in bringing together the results found so far.

AB - Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activation is broadly used and continually improved. However, a subset of patients eventually progresses to castration-resistant disease. To date, various mechanisms of resistance have been identified including the development of AR-independent aggressive variant prostate cancer based on neuroendocrine transdifferentiation (NED). Here, we review the highly complex processes contributing to NED. Genetic, epigenetic, transcriptional aberrations and posttranscriptional modifications are highlighted and the potential interplay of the different factors is discussed. Background Aggressive variant prostate cancer (AVPC) with traits of neuroendocrine differentiation emerges in a rising number of patients in recent years. Among others, advanced therapies targeting the androgen receptor axis have been considered causative for this development. Cell growth of AVPC often occurs completely independent of the androgen receptor signal transduction pathway and cells have mostly lost the typical cellular features of prostate adenocarcinoma. This complicates both diagnosis and treatment of this very aggressive disease. We believe that a deeper understanding of the complex molecular pathological mechanisms contributing to transdifferentiation will help to improve diagnostic procedures and develop effective treatment strategies. Indeed, in recent years, many scientists have made important contributions to unravel possible causes and mechanisms in the context of neuroendocrine transdifferentiation. However, the complexity of the diverse molecular pathways has not been captured completely, yet. This narrative review comprehensively highlights the individual steps of neuroendocrine transdifferentiation and makes an important contribution in bringing together the results found so far.

U2 - 10.1186/s13046-022-02255-y

DO - 10.1186/s13046-022-02255-y

M3 - SCORING: Review article

C2 - 35109899

VL - 41

JO - J EXP CLIN CANC RES

JF - J EXP CLIN CANC RES

SN - 1756-9966

IS - 1

M1 - 46

ER -